Key Takeaways
- Strong quarter despite sector headwinds: Revenue and profitability improved, with the glass-lined equipment business outperforming last year even as the broader chemical sector remains under pressure.
- Kinam acquisition unlocks oil & gas: The transformative Kinam deal delivered its first oil and gas order, a breakthrough management calls a potential "path breaker" that could change the subsidiary's entire trajectory.
- Thaletec margins jump on volume and mix: Thaletec's margin improvement was driven by higher revenue and a shift toward customized, differentiated products, while India margins stayed weak.
- Debt reduction accelerates: The company repaid INR 35 crores in the first half, targeting double that for the full year, funded by operating cash flow and working capital efficiencies.
- What to watch next quarter: Whether the pharma-driven order uptick converts into sustained revenue, the pace of Kinam's cross-selling into paints and petrochemicals, and any stabilization in India GLE margins.
Segment Performance & Drivers
- Glass-lined equipment (GLE): The core business continues to deliver exceptional results, outperforming last year. The quarter's uptick was predominantly pharma-driven, with an equal mix of chemical and pharma in India and a pharma skew internationally.
- Thaletec ramp: The innovative Thaletec range, launched in India two quarters ago, gained strong acceptance with close to 25 equipment either sold or under execution. Revenue exceeded INR 90 crores this quarter, a trend management expects to sustain broadly.
- Thaletec margin lift: Improvement was predominantly volume-driven (higher revenue) and also a function of product mix, with customized differentiated products in the orders sold this quarter. India margins, by contrast, remained very weak.
- Filtration & drying recovery: After slack order booking a few quarters back, good uptake and encouraging demand from pharma has built a healthier order book; orders will execute over the next two or three quarters.
- Kinam oil & gas breakthrough: Kinam made its first entry into the oil and gas industry last quarter. Management believes this could be a path breaker and change the entire trajectory for Kinam going forward.
- Service business composition: Pure after-sales service is currently ~7% of revenue, with an optimal level around 10%. Product upgradation and automation packages are reflected in the equipment business but form part of the service element for customers.
Nilesh Ganjwala: "Very interestingly, in the last quarter, Kinam for the first time has made a breakthrough into the oil and gas industry, and we believe that that could be a path breaker for the future and could really change the entire trajectory for Kinam going forward."
Order Book & Demand Visibility
- Order book visibility: The order book provides visibility for the next eight months in international business and five months in the domestic market.
- Chemical sector pressure easing: While the chemical sector remains under pressure, a turnaround was observed in order booking and pricing this quarter.
- Pharma revival driving momentum: Renewed momentum in filtration, drying and equipment segments, particularly in the southern region, was driven by revival in the pharmaceutical sector.
- Pharma revenue mix range: Pharma contribution will be retained within the historical range of 35% to 60% of revenue.
- US market opportunity: Management is confident of making inroads fairly quickly, citing the advantage of starting from a relatively low base and the ongoing shift of high-end pharma molecule manufacturing to the US, which demands high-end equipment regardless of the political situation.
Aalap Patel: "I think regardless of the political situation in the US, I think manufacturing continues to, especially for pharma products, continues to move to the US. And when these high-end molecules move to the US, I think high-end equipment is also needed."
Margins & Profitability
- GLE sustainable margins: Sustainable EBITDA margins in the GLE business range between 17% and 20% in the longer term; current margins reflect a slight downtick in the order book over the last two quarters.
- Thaletec sustainable margins: On a long-term sustainable basis, margins will be in the 15% to 17% range for Thaletec standalone.
- Filtration & drying margins: Sustainable margins are in the 16% to 18% range, even with current economics and dynamics.
- India vs Thaletec margin divergence: Thaletec margins have improved significantly, whereas India margins have continued to be very weak, a dynamic management did not quantify further.
- Interest cost reduction: Interest reduced quarter-on-quarter predominantly due to debt repayment; the conscious downsizing of debt is being funded out of operating and working capital efficiencies.
Aalap Patel: "I would say quality is not the differentiator for Thaletech. I think when it comes to quality, we really believe that having great quality is a matter of hygiene. Having great quality is not a differentiator."
Strategic Initiatives
- Kinam integration progressing: The third phase of integration is underway. Cross-selling into petrochemicals and paints is still a work in progress and will be approached over the coming quarters.
- CleanMax captive power JV: The company acquired a 26% stake in Clean Max Anchorage Private Limited for up to INR 3.36 crores to develop a captive solar (2.31 MWp) and wind (3.30 MW) facility in Gujarat, with a payback period expected around two years. Cost savings guidance was withheld due to NDA terms.
- Kinam amalgamation: Stock exchange approval has been received for the scheme of amalgamation of Kinam Enterprise Private Limited with HLE Glascoat Limited; the NCLT application is now in process.
- Thaletec pipeline in India: Many Thaletec innovations are still left to be inducted into the Indian market, suggesting a multi-quarter rollout runway.
- No China entry planned: Management has no plans to venture into the Chinese market, describing it as a very fragmented, crowded market with 20 to 30 different players, and not a priority at the moment.
Aalap Patel: "So, it's a very, very fragmented market with something like 20, 30 different players within the Chinese glasslined equipment market, all manufacturing a wide range of equipment and also sourcing from some vendors and not always manufacturing everything themselves. I think it's a very different dynamic and it's also a very, very crowded market. So, for us to make efforts to make any inroads into China is not a priority at the moment."
Balance Sheet & Capital Allocation
- Debt reduction pace: The company reduced debt by INR 35 crores in the first half of the year and expects to double that for the full year, implying a ~INR 70 crore reduction target.
- No growth capex planned: For the upcoming year, no capex project is planned; the company will stick to replacement capex only.
- Cash flow improvement: Lower interest costs will result in better cash flows, with repayments continuing from operating and profit efficiencies.
- Working capital discipline: Strong performance was aided by improved receivables and better working capital management, which improved operating cash flow.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Thaletec revenue run-rate | Revenue in excess of INR 90 crores per quarter broadly sustained | Ongoing quarters |
| Thaletec sustainable margins | 15% to 17% range for Thaletec standalone | Long-term |
| GLE sustainable EBITDA margins | 17% to 20% range | Longer term |
| Filtration & drying sustainable margins | 16% to 18% range | Even with current dynamics |
| Filtration & drying order execution | Orders from current healthier book will execute and reflect in numbers | Next 2–3 quarters |
| Debt reduction | INR 35 crores done in H1; should double it for the full year (~INR 70 crores) | FY25 full year |
| Pharma revenue mix | Retained within historical 35% to 60% range | Ongoing |
| Pure service revenue share | Optimal level up to 10% (from ~7% currently) | No date given |
| Capex | No capex project planned; replacement capex only | Upcoming year |
| CleanMax JV payback | Payback period expected in range of ~2 years | ~2 years from commissioning |
| Kinam amalgamation | NCLT application filing in process after stock exchange approval | In process |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Consolidated revenue | ₹236 cr, +5% YoY and +3.8% QoQ |
| EBITDA | ₹35.4 cr, +19% YoY and +50% QoQ |
| EBITDA margin | 15.0% |
| PAT | ~₹14 cr, +33% YoY and +166.1% QoQ |
| PAT margin | 6.1% |
| H1 FY25 revenue | ₹463 cr, +10% YoY |
| H1 FY25 EBITDA margin | 12.8% |
| Consolidated order book | ₹602 cr, +27% sequential growth as of Sep 2024 |
| Glass-lined equipment revenue | ₹144 cr, +18.4% YoY |
| Glass-lined equipment EBITDA | ₹20 cr, +124% YoY |
| Glass-lined equipment EBITDA margin | 13.4% |
| Filtration, drying and other equipment revenue | ₹65 cr, -36% YoY |
| Filtration, drying and other equipment EBITDA margin | 11% |
| Heat transfer equipment revenue | ₹25 cr, +17% QoQ |
| Debt repaid during the quarter | ₹35 cr |
| Thaletec revenue (last two quarters) | in excess of ₹90 cr per quarter |
| Thaletec sustainable long-term EBITDA margin | 15% to 17% |
| Glass-lined equipment sustainable long-term EBITDA margin | 17% to 20% |
| Filtration and drying sustainable long-term EBITDA margin | 16% to 18% |
| Glass-lined equipment market share (India) | 25% to 30% |
| Filtration and drying market share (domestic) | 50% to 60% |
| Pharma revenue contribution range | 35% to 60% of overall revenues historically |
| After-sales service revenue share | ~7% of sales, optimal level may go up to 10% |
| Export share from India business | 3% to 5% |